Taiji Group: Innovation and Technology as the core brand, with the wing as the guiding force, driving dual-wheel development toward becoming a world-class traditional Chinese medicine enterprise

In 2025, a year marked by deep adjustment and transformation in the pharmaceutical industry, Taiji Group has delivered a notably resilient performance. The company achieved full-year revenue of CNY 10.5 billion, with net profit attributable to shareholders of CNY 121 million, up 352.38% year over year. In addition, net operating cash flow amounted to CNY 584 million, showing a solid trend of improving from negative to positive. Selling expenses decreased 49.88% year over year, with clear results in cost and expense management. Moreover, the company’s pharmaceutical manufacturing segment demonstrated strong profit-generating capability with a gross margin of 46.04%; during the industry adjustment period, it strengthened its development base, laying a solid foundation for subsequent high-quality growth.

Building a Foundation for Sci-Tech Innovation and Revitalizing Marketing

Unlock New Growth Momentum

The pharmaceutical industry has entered a new stage of high-quality development. Industry challenges such as centralized procurement becoming normalized and increasingly homogeneous competition have piled up. Anchoring itself on a “dual engine” of technological innovation and marketing innovation, Taiji Group has found the right points to drive forward amid the wave of industrial upgrading.

On the R&D front, in 2025 the company carried out more than 60 key R&D projects, including 4 Class 1 new drugs and 2 Class 2 new drugs. Among them, the biologic semaglutide injection obtained a clinical approval letter. The extended-release oxycodone hydrochloride tablets entered the list of innovative drug applications in Chongqing at the end of March 2026, marking that the company’s innovation breakthroughs in niche pain management (medicines for 麻精镇痛) have gained recognition in the market. In addition, its classic proprietary Chinese medicine compound Huagai Granules received a marketing approval letter in Macau, becoming the first classic proprietary Chinese medicine compound product approved after the Macau pharmaceutical regulator’s establishment. On the brand marketing side, the company built a three-in-one sales system of “self-operated + agency + new retail.” Sales volume of Taiji Huoxiang Zhengqi Oral Liquid at the terminal grew 47% year over year, and sales from leading and top-100 chain pharmacies surpassed CNY 100 million. Tongtian Oral Liquid and Bi-sinusitis Oral Liquid both posted double-digit growth in sell-through. GTV’s total transaction value grew 30% year over year, with faster integration of online and offline channels.

Overall, the coordinated push of R&D and marketing has helped Taiji Group accumulate core momentum to get through the cycle, and also laid a solid basis for subsequent brand leapfrogging and sci-tech breakthroughs.

Industry “Brain” Empowers the Entire Value Chain

Sign Cooperation to Unite for Breakthroughs

In its ongoing deep cultivation of technological innovation, Taiji Group has consistently transformed its sci-tech strength into market competitiveness. Recently, the company convened a high-standard sci-tech conference to gather consensus on industrial development. On March 21, 2026, the “Zhengyuan Comes Forth · Ecological Co-integration” sci-tech innovation conference was held at Chongqing Yuzhou Hotel, drawing together more than 300 experts, scholars, and representatives from government and enterprises. This event became a concentrated display of Taiji Group’s technological strength. The release of the milestone initiative further marks Taiji Group’s leap from outputting a single product to becoming an “industrial ecosystem builder.”

At the conference, the “Modern Traditional Chinese Medicine Industry Brain” that Taiji Group built and operated was officially launched—coordinated by Chongqing’s Economic and Information Technology Commission, with the Fuling District government issuing the “call for bids” and leading the way. It works in conjunction with enterprises such as China Unicom and Huawei to build a digital service matrix. It connects with more than 500 suppliers to enable full-process quality traceability across the chain of “medicinal materials—decoction pieces—formulations.” Processing of traditional Chinese medicinal materials can reach 100,000 tons per year, becoming a core infrastructure for Chongqing to build a modern TCM industrial high ground.

At the industry-university-research-medical signing ceremony held on the same day, Taiji Group reached cooperation agreements with multiple organizations including West China Hospital of Sichuan University and Nanjing University of Chinese Medicine, connecting the entire chain from innovative R&D to clinical applications and industrial transformation. The results reports from the academician workstation for “Traditional Chinese Medicine Innovation Research” and the establishment of an inheritance and innovation studio for national TCM masters followed one after another, and a dual-engine driven model of “academician-led guidance + national TCM inheritance” has basically taken shape.

Anchoring the Brand-Strong Enterprise Strategy

Create a New Benchmark for the Taiji Brand

In recent years, guided by the national brand-strong strategy, Taiji Group has elevated brand building to the level of strategic priority, promoting its own high-quality development through brand-strong enterprise actions. On the day of the sci-tech conference, Taiji Group’s first “Taiji Brand Day” was formally launched. The company set March 21 every year as the enterprise’s brand day. Choosing this date is deeply thoughtful—coinciding with the Spring Equinox, when all things begin to grow, it aligns with the brand value of “Zhengyuan Comes Forth.” It also coincides with the first International Taijiquan Day, where Taiji culture and TCM culture share the same roots and origins. It further traces back to March 1972, when the Sichuan Fuling TCM factory was established, paying tribute to the entrepreneurial gene of half a century.

In its brand architecture, Taiji Group has built a three-tier matrix of “parent brand + sub-brands + product brands.” The parent brand, “Guoyao Taiji,” centers on the Taiji IP and creates the core image of “Taiji IP.” The three major sub-brands break through with differentiated positioning: Tongjungu and the Mianyang Pharmaceutical Factory dig deep into the heritage of over a century of intangible cultural legacy; the Fuling Pharmaceutical Factory highlights strengths in intelligent manufacturing; and Southwest Pharmaceutical focuses on R&D of innovative modern drugs. With a precise “4+1” product pipeline, Taiji Huoxiang Zhengqi Oral Liquid and Jizhi Syrup, both consecutive category leaders, were selected for the “Annual China OTC Golden Single Product” list. Potential products such as the semaglutide injection are also targeting the trillion-yuan market.

From establishing the first “Taiji Brand Day,” to launching the modern TCM industry brain, to constructing an ecosystem across industry-university-research-medical collaboration, Taiji Group is moving forward with “Zhengyuan Comes Forth, Excellence Pursued” as its core—completing a triple leap from being a traditional TCM inheritor to an innovator of modern TCM, and then to an ecosystem builder for Chinese medicine. At the new starting point of the “15th Five-Year Plan and 6th Five-Year Plan” (i.e., the opening of the 15/5 period), Taiji Group is accelerating toward the grand goal of “world-class TCM enterprises,” with technological innovation as its wings and brand culture as its sail.